All In Biotech

Drug Trial Radar · NCT07174843

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of BZE2204 CD19/CD22/BCMA CAR-T Cells in Subjects With Relapsed or Refractory Active Autoimmune Diseases

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 9, 2025

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, early-phase dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of autologous CD19/CD22/BCMA trispecific CAR T cells (BZE2204) in patients with relapsed or refractory autoimmune diseases, including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM) and immune thrombocytopenia (ITP). BZE2204 is manufactured using a rapid, approximately 6-hour process without ex vivo cell expansion and administered without lymphodepleting chemotherapy. The main safety, efficacy and exploratory assessments are conducted through Month 6 after infusion, followed by an extended follow-up phase.

Conditions

  • Idiopathic Inflammatory Myopathies(IIM)
  • Immune Thrombocytopenia(ITP)
  • Systemic Lupus Erythematosus(SLE)

Interventions

  • CD19/CD22/BCMA CAR-T cells(BZE2204)Biological

    Participants undergo leukapheresis for the collection of autologous peripheral blood mononuclear cells. T cells are engineered to express a trispecific chimeric antigen receptor targeting CD19, CD22 and BCMA through a rapid manufacturing process without ex vivo cell expansion. Participants receive a single intravenous infusion of BZE2204 on Day 0 without prior lymphodepleting chemotherapy. The SLE cohort received a target dose of 5 × 10⁵ CAR-positive T cells/kg. Dose levels for other cohorts are determined according to the approved dose-escalation and expansion protocol. The approximately 6-hour manufacturing process does not include the complete leukapheresis-to-infusion interval.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events and Serious Adverse EventsTime frame: From leukapheresis through Month 6 after infusion
  2. Incidence of Dose-Limiting ToxicitiesTime frame: Day 0 through Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mengchao Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.